CN113081988B - Cefradine dispersible tablet and preparation method thereof - Google Patents

Cefradine dispersible tablet and preparation method thereof Download PDF

Info

Publication number
CN113081988B
CN113081988B CN202110507598.3A CN202110507598A CN113081988B CN 113081988 B CN113081988 B CN 113081988B CN 202110507598 A CN202110507598 A CN 202110507598A CN 113081988 B CN113081988 B CN 113081988B
Authority
CN
China
Prior art keywords
cefradine
dispersible tablet
parts
preparation
drying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110507598.3A
Other languages
Chinese (zh)
Other versions
CN113081988A (en
Inventor
律涛
刘彦
李程
杨少坤
薛忠
王嫚
张静岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Medical University
Original Assignee
Hebei Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Medical University filed Critical Hebei Medical University
Priority to CN202110507598.3A priority Critical patent/CN113081988B/en
Publication of CN113081988A publication Critical patent/CN113081988A/en
Application granted granted Critical
Publication of CN113081988B publication Critical patent/CN113081988B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a cefradine dispersible tablet and a preparation method thereof, wherein the cefradine dispersible tablet comprises the following components in parts by weight: 250 parts of cefradine, 37-41 parts of mannitol, 8-12 parts of carboxymethyl starch sodium, 8 parts of taura, 5 parts of guar gum, 8-12 parts of microcrystalline cellulose, 22-28 parts of carboxymethyl starch sodium and 2 parts of magnesium stearate. After 6 months of accelerated stability tests, the content of specific impurities, friability and dissolution rate of the cefradine dispersible tablet prepared by the invention meet the standards, and the treatment effect of the medicine during storage is ensured.

Description

Cefradine dispersible tablet and preparation method thereof
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a cefradine dispersible tablet and a preparation method thereof.
Background
Chemical name of cefradine: (6R,7R) -7- [ (R) -2-amino-2- (1, 4-cyclohexadien-1-yl) acetylamino ] -3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid of formula: C16H19N3O4S, molecular weight: 349.40. the structural formula is as follows:
Figure GDA0003688594730000011
cefradine is beta-lactam antibiotic and is used for treating respiratory tract infection such as acute pharyngitis, tonsillitis, otitis media, bronchitis and pneumonia caused by sensitive bacteria, urogenital tract infection, skin and soft tissue infection and the like; the cefradine has wide market application, but has unstable chemical property, high impurity content, easy hydrolysis and other problems in the storage process, thereby not only influencing the quality of the product, but also bringing potential safety hazards to clinical application.
The dispersible tablet is an excellent new formulation developed in recent years and has the reputation of solid oral liquid. It integrates the advantages of tablet and liquid preparation, and overcomes the disadvantages of both. Has the following characteristics: 1. the disintegration time is short, and the dispersion state is good; 2. the medicine is dissolved out quickly and absorbed quickly; 3. the oral liquid is convenient to take and various in taking method, can be directly swallowed or dispersed in water for taking, and is particularly suitable for old, young and dysphagia patients; 5. the dispersible tablet has simple production process, and can be produced by using common tablet production equipment.
Disclosure of Invention
The invention aims to solve the problems of poor stability, easy generation of degradation impurities and the like of the cefradine dispersible tablet in storage, can effectively reduce the content of specific degradation impurities such as cefalexin, 7-aminodesacetoxycephalosporanic acid, cefradine polymer and the like in the preparation by controlling the weight ratio of mannitol, taurine and guar gum in a prescription, can keep the specific degradation impurities slowly growing after the medicine is placed for a long time, is favorable for the long-term stability of the preparation, and ensures the safety of the medicine.
Firstly, the invention provides a cefradine dispersible tablet which comprises the following components in parts by weight:
Figure GDA0003688594730000021
further, the microcrystalline cellulose is microcrystalline cellulose with the bulk density of 0.35-0.46g/ml and the average grain diameter of 50-60 microns, and preferably the microcrystalline cellulose is PH 301.
Adding adjuvants, and mixing with active ingredients or other adjuvants by "internal addition method" to make into granule.
Further, mannitol: taurine: guar gum ═ (7.4-8.2): 1.6: 1; preferably, the ratio of mannitol: taurine: guar gum-8: 1.6:1
Further, the cefradine dispersible tablet contains 500mg, preferably 250mg of cefradine 125-.
Further, the invention provides a cefradine dispersible tablet which comprises the following components in percentage by weight:
Figure GDA0003688594730000022
further, the invention provides a preparation method of the cefradine dispersible tablet composition.
A preparation method of a cefradine dispersible tablet is characterized by comprising the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent into water to prepare a guar gum solution with the concentration of 4.5-5.5% (w/w);
(2) premixing and wet granulating: firstly adding the cefradine and the internally added auxiliary materials into a wet mixing granulator for premixing, then adding the adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying the wet granules with a boiling granulator, wherein the moisture content is not higher than 1.5%.
(4) Straightening: adding the dried granules into a granulating machine for granulating;
(5) mixing: adding microcrystalline cellulose and sodium carboxymethyl starch into the granules, mixing for 10-15 minutes, adding magnesium stearate, and mixing for 3-5 minutes.
(6) Tabletting: tabletting under the pressure of 9-12KN to obtain the cefradine dispersible tablet.
In the preparation method, in the drying in the step (3), the wet granules are dried by a boiling granulator, and a low-temperature drying technology is adopted, wherein the air inlet temperature is set to be 45 ℃, the air outlet temperature is set to be 38 ℃, the material temperature is 41 ℃, and the moisture is measured by sampling, and reaches below 1.5%.
In the preparation method, the concentration of the guar gum solution in the preparation of the binder solution in the step (1) is 5.0%.
In the preparation method, in the step (6), the tabletting pressure is 10 KN.
The inventor screens a better prescription proportion of a dispersible tablet preparation and a preparation process thereof through a large number of experiments, (1) by controlling the dosage of mannitol, a stabilizer taurine and an adhesive guar gum with a specific proportion are added to form mannitol: taurine: guar gum ═ (7.4-8.2): 1.6:1, the addition of taurine and guar gum plays a role in protecting cefradine raw materials, the cefradine dispersible tablet prepared by the method effectively controls specific degradation impurities such as cephalexin, 7-aminodesacetoxycephalosporanic acid, cefradine polymer and the like through the synergistic effect of the three components, and (2) the brittleness and the dissolution rate of the prepared cefradine dispersible tablet meet the standard through controlling the concentration of guar gum serving as a binding agent and the stacking density and the particle size of microcrystalline cellulose, and the dissolution rate meets the standard through an accelerated stability test for 6 months, so that the treatment effect of the medicine during storage is ensured.
Detailed Description
The invention discloses a cefradine dispersible tablet and a preparation method thereof, and the cefradine dispersible tablet can be realized by combining the relevant principles of pharmaceutical preparations and properly improving the process parameters by taking the contents of the invention as reference. It is expressly intended that all such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the scope of the invention. While the invention has been described in terms of preferred embodiments, it will be apparent to those skilled in the art that variations may be applied, or changes and combinations may be made, in the methods and applications described herein to achieve and use the inventive techniques without departing from the spirit, scope, and content of the invention.
For a better understanding of the invention, and not as a limitation on the scope thereof, all numbers expressing quantities, percentages, and other numerical values used in this application are to be understood as being modified in all instances by the term "about". At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
The cefradine and the auxiliary materials are all sold in the market.
The present invention is further illustrated by the following examples, which are not intended to limit the invention in any way.
Content uniformity: measured according to the content uniformity inspection method (general rule 0941 method) of the four parts of the national pharmacopoeia 2015 edition.
Friability: the measurement was carried out according to the friability test method for four parts (general rule 0923) of the year 2015 version, China pharmacopoeia.
Cephalexin, 7-aminodesacetoxycephalosporanic acid, cephradine polymer: the quality standard of cefradine is determined according to the second part of cefradine in the year 2015 of Chinese pharmacopoeia.
(1) Dissolution medium:
ph1.2 hydrochloric acid solution: 7.65ml of concentrated hydrochloric acid are weighed out with a measuring cylinder and diluted to 1000ml with water.
(2) A dissolution device: a paddle method; rotating speed: 50 revolutions per minute; volume of medium: 900 ml; temperature: 37.0 +/-0.5 ℃; sampling volume: 7 ml;
(3) the standard is as follows: and the dissolution rate is not lower than 80% in 45 min.
Dispersion uniformity: the measurement is carried out according to "disintegration time limit inspection method" (0921 in the four general guidelines of the pharmacopoeia 2015 edition of China). The method comprises the following specific steps: checking according to disintegration time limit method, hanging the hanging basket on a metal bracket through a stainless steel shaft at the upper end, immersing the hanging basket in a 1000ml beaker, adjusting the position of the hanging basket to enable the hanging basket to fall to a low point, wherein the screen is 25mm away from the bottom of the beaker, and the water temperature is 15-25 ℃; the inner diameter of a sieve pore of the stainless steel screen is 710 microns; the screen is 15mm below the liquid level when the liquid level is adjusted to enable the basket to rise, and the top of the basket cannot be immersed in the solution. Taking 6 tablets of the product, respectively placing the tablets in glass tubes of the hanging baskets, immediately starting a disintegration tester for checking, and completely disintegrating each tablet within 3.0 minutes and passing through a screen mesh.
Test example 1: prescription screening
1. The prescription composition is as follows:
Figure GDA0003688594730000041
Figure GDA0003688594730000051
2. the preparation method comprises the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent in water to prepare a guar gum solution with the concentration of 5.0% (w/w);
(2) premixing and wet granulation: firstly adding the cefradine and the internally added auxiliary materials into a wet mixing granulator for premixing, then adding the adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying wet granules by a boiling granulator by adopting a low-temperature drying technology, wherein the air inlet temperature is set to be 45 ℃, the air outlet temperature is set to be 38 ℃, the material temperature is 41 ℃, sampling is carried out to measure the moisture content, the moisture content reaches below 1.5 percent, and the drying time is about 35min after the drying is finished;
(4) straightening: adding the dried granules into a granulating machine for granulating;
(5) mixing: adding microcrystalline cellulose and sodium carboxymethyl starch into the granules, mixing for 10-15 minutes, adding magnesium stearate, and mixing for 3-5 minutes.
(6) Tabletting: tabletting under 10KN pressure to obtain cefradine dispersible tablet;
samples with different prescription ratios are subjected to an accelerated stability test under the conditions of 40 ℃ and 75% +/-5% relative humidity, and the specific degradation impurity condition is detected at 6 months, and the results are shown in table 1.
TABLE 1 Table of specific impurity levels at 6 months of accelerated stability testing for samples produced according to different recipes
Figure GDA0003688594730000061
As shown in Table 1, through an accelerated stability test for 6 months, a more optimal formula ratio of the preparation is screened, the content of taurine is found to have great influence on the stability of the cephradine dispersible tablets, and in addition, the formula is further optimized by adding a filler mannitol and an adhesive guar gum in a specific ratio, so that specific degradation impurities such as cephalexin, 7-aminodesacetoxycephalosporanic acid, cephradine polymer and the like are effectively controlled. The optimal prescription range obtained finally is 37-41 parts of mannitol, 8 parts of taurine and 5 parts of guar gum, namely the mannitol is formed: taurine: guar gum ═ (7.4-8.2): 1.6:1, the cefradine dispersible tablet prepared by the method meets the standard of each specific impurity through an accelerated stability test for 6 months.
Example 1: cefradine dispersible tablet
1. The prescription composition is as follows:
Figure GDA0003688594730000071
1000 tablets are dosed according to the prescription to prepare the cefradine dispersible tablets, the same applies below
2. The preparation method comprises the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent in water to prepare a guar gum solution with the concentration of 5.0% (w/w);
(2) premixing and wet granulation: firstly adding cefradine, mannitol, sodium carboxymethyl starch and taurine into a wet mixing granulator for premixing, then adding an adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying wet granules by using a boiling granulator, adopting a low-temperature drying technology, setting the air inlet temperature to be 45 ℃, the air outlet temperature to be 38 ℃, the material temperature to be 41 ℃, sampling and measuring the moisture, wherein the moisture reaches 1.2 percent, and after drying, the drying time is about 35 min;
(4) straightening: adding the dried granules into a granulating machine for granulating;
(5) mixing: adding microcrystalline cellulose and sodium carboxymethyl starch into the granules, mixing for 12 min, adding magnesium stearate, and mixing for 4 min.
(6) Tabletting: tabletting under 10KN pressure to obtain cefradine dispersible tablet;
3. and (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 2.
Table 2: EXAMPLE 1 friability, Dispersion uniformity, dissolution results for dispersible tablets of cefradine
Figure GDA0003688594730000081
Example 2: cefradine dispersible tablet
1. The prescription composition is as follows:
Figure GDA0003688594730000082
2. the preparation method comprises the following steps: the same as in example 1.
3. And (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 3.
Table 3: example 2 results of friability, dispersion uniformity, dissolution of cefradine dispersible tablets
Figure GDA0003688594730000083
Example 3: cefradine dispersible tablet
1. The prescription composition is as follows:
Figure GDA0003688594730000091
2. the preparation method comprises the following steps: the same as in example 1.
3. And (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared dispersible tablets of cephradine were measured, and the results are shown in table 43.
Table 4: example 3 results of friability, dispersion uniformity, dissolution of cefradine dispersible tablets
Figure GDA0003688594730000092
Example 4: cefradine dispersible tablet
1. The prescription composition is as follows:
Figure GDA0003688594730000101
2. the preparation method comprises the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent in water to prepare a guar gum solution with the concentration of 4.5% (w/w);
(2) premixing and wet granulation: firstly adding cefradine, mannitol, sodium carboxymethyl starch and taurine into a wet mixing granulator for premixing, then adding an adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying wet granules by using a boiling granulator, adopting a low-temperature drying technology, setting the air inlet temperature to be 45 ℃, the air outlet temperature to be 38 ℃, the material temperature to be 41 ℃, sampling and measuring the moisture, wherein the moisture reaches 1.2 percent, and after drying, the drying time is about 35 min;
(4) straightening: adding the dried particles into a granulating machine for granulating;
(5) mixing: the microcrystalline cellulose and sodium carboxymethyl starch are added into the granules, mixed for 12 minutes, then added with magnesium stearate, and mixed for 5 minutes.
(6) Tabletting: tabletting under 11KN pressure to obtain cefradine dispersible tablet;
3. and (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 5.
Table 5: example 4 results of friability, dispersion uniformity, dissolution of cefradine dispersible tablets
Figure GDA0003688594730000111
Example 5: cefradine dispersible tablet
1. The prescription composition is as follows:
Figure GDA0003688594730000112
2. the preparation method comprises the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent in water to prepare a guar gum solution with the concentration of 5.5% (w/w);
(2) premixing and wet granulation: firstly adding cefradine, mannitol, sodium carboxymethyl starch and taurine into a wet mixing granulator for premixing, then adding an adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying wet granules by using a boiling granulator, adopting a low-temperature drying technology, setting the air inlet temperature to be 45 ℃, the air outlet temperature to be 38 ℃, the material temperature to be 41 ℃, sampling and measuring the moisture, wherein the moisture reaches 1.3 percent, and after drying, the drying time is about 35 min;
(4) straightening: adding the dried granules into a granulating machine for granulating;
(5) mixing: adding microcrystalline cellulose and sodium carboxymethyl starch into the granules, mixing for 10 min, adding magnesium stearate, and mixing for 5 min.
(6) Tabletting: tabletting under the pressure of 9KN to obtain the cefradine dispersible tablet;
3. and (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 6.
Table 6: example 5 results of friability, dispersion uniformity, dissolution of cefradine dispersible tablets
Figure GDA0003688594730000121
Comparative example 1: effect of guar concentration on dissolution
1. The prescription composition is as follows: the same as in example 1.
2. The preparation method comprises the following steps: the procedure of step (1) is as follows, and the rest of the procedure is the same as in example 1.
Figure GDA0003688594730000122
3. And (3) detection results:
the friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 7.
Table 7: comparative example 1 results of friability, dispersion uniformity and dissolution of cefradine dispersible tablets
Figure GDA0003688594730000123
As can be seen from Table 7: comparative analysis examples 1-5 and comparative examples 1-1 and 1-2, the concentration of the binder guar gum affects the friability and dissolution of the cephradine dispersible tablets. When the concentration of the adhesive is lower, for example, lower than 4.5% (for example, 4%), the dissolution of the dispersible tablet is slow, and the dissolution rate in 45min is only 75.1%, which is not satisfactory. ② when the concentration of the binder is higher, for example higher than 5.5% (for example 6%), the friability of the dispersible tablet is not satisfactory.
In conclusion, the concentration of the guar gum is 4.5% -5.5%.
Comparative example 2: effect of microcrystalline cellulose bulk Density and particle size
1. The prescription composition is as follows: microcrystalline cellulose having different bulk densities and particle sizes was used, as shown in the following table, and the rest was the same as in example 1.
Figure GDA0003688594730000131
2. The preparation method comprises the following steps: the same as in example 1.
3. The result of the detection
The friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 8.
Table 8: comparative example 2 results of friability, dispersion uniformity and dissolution of cefradine dispersible tablet
Figure GDA0003688594730000132
As can be seen from Table 8: comparative analysis examples 1-5 and comparative example 2, the dissolution of the cefradine dispersible tablet is influenced by different types of microcrystalline cellulose with different bulk densities and particle sizes, wherein the microcrystalline cellulose preferably has the bulk density of 0.35-0.46g/ml and the average particle size of 50-60 microns, and more preferably has the microcrystalline cellulose PH 301.
Comparative example 3: influence of drying Process in step (3)
1. The prescription composition is as follows: the same as in example 1.
2. The preparation method comprises the following steps: the procedure (3) is as follows, and the rest of the procedure is the same as in example 1.
Figure GDA0003688594730000141
3. The result of the detection
The friability, dispersion uniformity and dissolution of the prepared cefradine dispersible tablets were measured, and the results are shown in table 9.
Table 9: comparative example 3 results of friability, dispersion uniformity and dissolution of cefradine dispersible tablets
Figure GDA0003688594730000142
From table 9 in combination with example 6: comparative analysis examples 1-5 and comparative example 3, the drying process affects the content of polymer impurities in the cephradine tablet, and the cephradine dispersible tablet prepared in comparative example 3 is accelerated to stand for 6 months, and the content of the cephradine polymer is significantly increased, which is not satisfactory (see example 6).
Example 6: stability survey
The cefradine dispersible tablets prepared in the examples 1-5 and the comparative example 3 are selected respectively to be examined by an accelerated stability test, and after being placed for 6 months under the long-term conditions of the temperature of 40 ℃ and the relative humidity of 75% +/-5%, the specific impurities and the dissolution rate are tested, and the test results are shown in table 10.
Table 10: accelerated stability survey data
Figure GDA0003688594730000151
As can be seen from table 3: compared with the comparative example 3, the content of specific impurities prepared in the examples 1 to 5 of the invention is lower, especially the content of the cephradine polymer, the cefradine polymer is not detected at the time of accelerating 6 months, the content of other impurities is also obviously lower than that of the comparative example 3, and the results show that the cefradine dispersible tablets prepared in the examples 1 to 5 of the invention have better stability.
The above is only a preferred embodiment of the present invention, and it should be understood that the present invention is not limited thereto, and those skilled in the art can make various modifications, decorations and equivalents without departing from the principle of the present invention, and therefore, the present invention is to be covered within the protection scope of the present invention.

Claims (6)

1. A cefradine dispersible tablet comprises the following components in parts by weight:
Figure FDA0003688594720000011
the microcrystalline cellulose is microcrystalline cellulose PH301 with the bulk density of 0.35-0.46mg/ml and the average grain diameter of 50-60 microns;
the preparation method comprises the following steps:
(1) preparation of adhesive solution: dissolving guar gum serving as a binding agent into water to prepare a guar gum solution with the concentration of 4.5-5.5%;
(2) premixing and wet granulation: firstly adding the cefradine and the internal auxiliary materials into a wet mixing granulator for premixing, then adding the adhesive solution under the stirring condition, and carrying out wet granulation;
(3) and (3) drying: drying the wet granules with a boiling granulator, wherein the moisture content is not higher than 1.5%.
(4) Straightening: adding the dried granules into a granulating machine for granulating;
(5) mixing: adding microcrystalline cellulose and sodium carboxymethyl starch into the granules, mixing for 10-15 minutes, adding magnesium stearate, and mixing for 3-5 minutes.
(6) Tabletting: tabletting under 9-12KN to obtain the cefradine dispersible tablet.
The step (3) is drying: drying wet granules by a boiling granulator by adopting a low-temperature drying technology, wherein the air inlet temperature is set to be 45 ℃, the air outlet temperature is set to be 38 ℃, the material temperature is 41 ℃, and sampling is carried out to measure the moisture content, so that the moisture content is below 1.5 percent.
2. The dispersible tablet according to claim 1, comprising the following components in parts by weight:
Figure FDA0003688594720000012
Figure FDA0003688594720000021
3. the dispersible tablet according to claim 1, wherein the dispersible tablet comprises 250mg of cefradine 125-.
4. The dispersible tablet according to claim 3, comprising 250mg of cefradine.
5. The dispersible tablet according to claim 1, wherein in the preparation process, the guar gum solution is prepared in step (1) with a concentration of 5.0%.
6. The dispersible tablet according to claim 1, wherein in the step (6) of tabletting, the compression pressure is 10 KN.
CN202110507598.3A 2021-05-10 2021-05-10 Cefradine dispersible tablet and preparation method thereof Active CN113081988B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110507598.3A CN113081988B (en) 2021-05-10 2021-05-10 Cefradine dispersible tablet and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110507598.3A CN113081988B (en) 2021-05-10 2021-05-10 Cefradine dispersible tablet and preparation method thereof

Publications (2)

Publication Number Publication Date
CN113081988A CN113081988A (en) 2021-07-09
CN113081988B true CN113081988B (en) 2022-07-12

Family

ID=76664843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110507598.3A Active CN113081988B (en) 2021-05-10 2021-05-10 Cefradine dispersible tablet and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113081988B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032489A (en) * 2006-03-08 2007-09-12 上海秀新臣邦医药科技有限公司 Cefprozil dispersible table and the preparing method
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof
CN101401810A (en) * 2008-11-17 2009-04-08 北京诚创康韵医药科技有限公司 Dispersible tablet containing Cefixime and preparation method thereof
CN107496430A (en) * 2017-09-13 2017-12-22 南通荣成医药化工有限公司 A kind of Cefradine pharmaceutical composition
CN109692162A (en) * 2017-10-23 2019-04-30 康普药业股份有限公司 A kind of Cefradine pharmaceutical preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093738A1 (en) * 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032489A (en) * 2006-03-08 2007-09-12 上海秀新臣邦医药科技有限公司 Cefprozil dispersible table and the preparing method
CN101352424A (en) * 2008-09-16 2009-01-28 天津市中央药业有限公司 Cefdinir dispersible tablet and preparation method thereof
CN101401810A (en) * 2008-11-17 2009-04-08 北京诚创康韵医药科技有限公司 Dispersible tablet containing Cefixime and preparation method thereof
CN107496430A (en) * 2017-09-13 2017-12-22 南通荣成医药化工有限公司 A kind of Cefradine pharmaceutical composition
CN109692162A (en) * 2017-10-23 2019-04-30 康普药业股份有限公司 A kind of Cefradine pharmaceutical preparation

Also Published As

Publication number Publication date
CN113081988A (en) 2021-07-09

Similar Documents

Publication Publication Date Title
Bianchini et al. Influence of extrusion-spheronization processing on the physical properties of d-indobufen pellets containing pH adjusters
CN109248155B (en) Roxithromycin capsule and preparation process thereof
CN114288257B (en) Fluvoxamine maleate tablet and preparation method thereof
CN103610677A (en) Repaglinide troche and preparation method thereof
CN113081988B (en) Cefradine dispersible tablet and preparation method thereof
US20080132456A1 (en) Pharmaceutical Formulation Comprising Low Crystallinity Cellulose
CN112791054A (en) Dry granulation method of dry suspension
CN111603452B (en) Application of beta-glucan as binder in preparation of tablets or granules
CN114272219A (en) Donepezil hydrochloride tablet and preparation method thereof
CN109730969B (en) Lactic acid levofloxacin dispersible tablet and preparation method thereof
CN1723901A (en) Fleroxacin lactate dispersion tablet, and its prepn. method
CN108498481B (en) Cefixime composition and preparation method thereof
CN112704668A (en) Pramipexole dihydrochloride sustained-release composition
CN112190556A (en) Compound sulfamethoxazole trimethoprim tablet and preparation method thereof
Gaikwad et al. Development of controlled release spheroids using Buchanania cochinchinesis gum.
CN114983964B (en) Cefdinir granule and preparation method thereof
CN107080738A (en) The preparation method of acetylspiramycin tablet
CN117045610B (en) High-stability dissolution labetalol hydrochloride composition and preparation method thereof
CN113908134B (en) Preparation method of cefadroxil dispersion coated tablet
CN112618499B (en) Glimepiride dispersible tablet composition and preparation method thereof
CN116270487B (en) Pediatric paracetamol, chlorphenamine maleate granules and preparation method thereof
CN104414988A (en) Dasatinib tablet and preparation process thereof
CN115607518B (en) Texazolamide phosphate tablet and preparation method thereof
CN115501196B (en) Preparation method of roxithromycin dispersible tablet
CN114028369B (en) Amitriptyline hydrochloride preparation composition and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant